Deepak L Bhatt

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Effect of platelet inhibition with cangrelor during PCI on ischemic events
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02132, USA
    N Engl J Med 368:1303-13. 2013
  2. doi request reprint Controversies in non-ST-elevation acute coronary syndromes and percutaneous coronary interventions
    Deepak L Bhatt
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Cleve Clin J Med 77:101-9. 2010
  3. doi request reprint Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02132, USA
    JAMA 304:1350-7. 2010
  4. doi request reprint Intravenous platelet blockade with cangrelor during PCI
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 361:2330-41. 2009
  5. doi request reprint Acute coronary syndrome update for hospitalists
    Deepak L Bhatt
    Cardiology, VA Boston Healthcare System, Boston, Massachusetts, USA
    J Hosp Med 5:S15-21. 2010
  6. doi request reprint Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
  7. doi request reprint Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet f
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Boston Children s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 61:872-9. 2013
  8. doi request reprint Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:223-31. 2008
  9. doi request reprint Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program
    Michelle L O'Donoghue
    Cardiovascular Division and TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 34:36-43. 2012
  10. doi request reprint Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 105:445-52. 2010

Collaborators

Detail Information

Publications50

  1. doi request reprint Effect of platelet inhibition with cangrelor during PCI on ischemic events
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02132, USA
    N Engl J Med 368:1303-13. 2013
    ..Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects...
  2. doi request reprint Controversies in non-ST-elevation acute coronary syndromes and percutaneous coronary interventions
    Deepak L Bhatt
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Cleve Clin J Med 77:101-9. 2010
    ..Recent studies have helped clarify treatment strategies. Drug-eluting stents have reduced the problem of restenosis, but questions remain about the length of time patients need dual antiplatelet therapy...
  3. doi request reprint Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02132, USA
    JAMA 304:1350-7. 2010
    ..Prior ischemic events, polyvascular disease, and diabetes mellitus have all been identified as predictors of ischemic events, but their comparative contributions to future risk remain unclear...
  4. doi request reprint Intravenous platelet blockade with cangrelor during PCI
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 361:2330-41. 2009
    ..Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI)...
  5. doi request reprint Acute coronary syndrome update for hospitalists
    Deepak L Bhatt
    Cardiology, VA Boston Healthcare System, Boston, Massachusetts, USA
    J Hosp Med 5:S15-21. 2010
    ..Understanding and implementing the recommendations in these evidence-based guidelines are important parts of hospitalists' practice...
  6. doi request reprint Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
    ..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel...
  7. doi request reprint Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet f
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Boston Children s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 61:872-9. 2013
    ..This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully account for the variability in clopidogrel pharmacokinetics and pharmacodynamics...
  8. doi request reprint Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:223-31. 2008
    ..The updated STEMI tools are available to clinicians online on the STRIVE Website...
  9. doi request reprint Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program
    Michelle L O'Donoghue
    Cardiovascular Division and TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 34:36-43. 2012
    ..Although atopaxar increased the concentration of Lp-PLA(2) and IL-18, the clinical relevance of these findings remains unknown and warrants further investigation and validation...
  10. doi request reprint Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 105:445-52. 2010
    ..In conclusion, approximately 1/4 of US patients with vascular disease are not treated with aspirin for secondary prevention, and 15% are not treated with any antithrombotic agent...
  11. doi request reprint Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry
    Amit Kumar
    Department of Hospital Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Crit Pathw Cardiol 8:104-11. 2009
    ..Few data are available for outpatients in actual clinical practice, especially those without known heart disease treated by physicians trained in different specialties across the geographic regions of the United States...
  12. doi request reprint Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial
    Michelle L O'Donoghue
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 123:1843-53. 2011
    ..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS...
  13. doi request reprint Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Am Coll Cardiol 62:286-90. 2013
    ....
  14. doi request reprint Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, and Harvard Medical School, Boston, USA
    N Engl J Med 369:1317-26. 2013
    ..The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear...
  15. doi request reprint Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis
    Dharam J Kumbhani
    Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Eur Heart J 34:1204-14. 2013
    ....
  16. doi request reprint Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program
    Samip Vasaiwala
    Division of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cardiol 35:541-7. 2012
    ..We studied the impact of chronic renal insufficiency on mortality and quality of inpatient care for AMI from the American Heart Association's Get With The Guidelines-Coronary Artery Disease Program...
  17. doi request reprint Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, TIMI Study Group, Harvard Medical School, Boston, MA, USA
    Lancet 382:605-13. 2013
    ..We assessed outcomes from the TRILOGY ACS trial based on whether or not patients had coronary angiography before treatment was chosen...
  18. ncbi request reprint The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, 1400 VFW Parkway, Boston, MA 02132, USA
    Eur Heart J 33:2143-50. 2012
    ..We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events...
  19. doi request reprint Predictors of adherence to performance measures in patients with acute myocardial infarction
    Dharam J Kumbhani
    Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Med 126:74.e1-9. 2013
    ..To understand how such gaps in recommended care may be narrowed further, it may be useful to determine those factors associated with lessened adherence to guideline-based care...
  20. doi request reprint Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines
    Pei Hsiu Huang
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cardiol 35:396-403. 2012
    ..Using data from GWTG, we examined trends associated with the smoking-cessation counseling (SCC) performance measure...
  21. doi request reprint Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA, USA
    Eur Heart J 30:1195-202. 2009
    ....
  22. doi request reprint Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients
    Bradley A Maron
    Department of Cardiology, Veterans Affairs Boston Healthcare System, Parkway, Boston, MA
    Circ Heart Fail 6:906-12. 2013
    ..Pulmonary hypertension (PH) is a key contributor to cardiovascular morbidity and early mortality; however, reports are lacking on the epidemiology of PH in at-risk patient populations...
  23. doi request reprint Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation
    Pei Hsiu Huang
    Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Crit Pathw Cardiol 11:177-85. 2012
    ....
  24. doi request reprint Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus
    Jacob A Udell
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Clin Cardiol 35:722-9. 2012
    ..In this review, we provide recommendations for the use of statins and aspirin for the prevention of cardiovascular events in high-risk patients with diabetes mellitus...
  25. ncbi request reprint Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary
    David P Faxon
    Brigham and Women s Hospital, 1620 Tremont St, Boston, MA 02120, USA
    Circ Cardiovasc Interv 4:522-34. 2011
    ....
  26. doi request reprint The state of periprocedural antiplatelet therapy after recent trials
    Nihar R Desai
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 3:571-83. 2010
    ....
  27. ncbi request reprint Clinical trials update from the annual scientific session of the American College of Cardiology 2006
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:36Q-41Q. 2006
  28. doi request reprint Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:43-81. 2008
    ..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS...
  29. pmc Paradoxical association of smoking with in-hospital mortality among patients admitted with acute ischemic stroke
    Syed F Ali
    Department of Neurology, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    J Am Heart Assoc 2:e000171. 2013
    ..We sought to determine if this effect was present in patients hospitalized with ischemic stroke...
  30. doi request reprint Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry
    Christian T Ruff
    TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA Electronic address
    Int J Cardiol 170:413-8. 2014
    ..Patients with atrial fibrillation (AF) are at increased risk of thromboembolic events. The long-term prognostic implications of AF in patients with atherothrombosis are unknown...
  31. doi request reprint Rivaroxaban in patients with a recent acute coronary syndrome
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 366:9-19. 2012
    ..Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome...
  32. doi request reprint Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)
    Hector M Medina
    Cardiac MR, PET, CT Program, Department of Radiology, Division of Cardiology, Massachusetts General Hospital, Boston, USA
    Am Heart J 162:283-290.e2. 2011
    ..To determine the adherence to national guidelines and in-hospital mortality of older patients with acute myocardial infarction (AMI) using a national database...
  33. doi request reprint A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Am Coll Cardiol 59:1304-11. 2012
    ..The aim of this study was to assess the effects of different proton pump inhibitors (PPIs) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel...
  34. doi request reprint Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective
    David P Faxon
    Division of Cardiology, Brigham and Women s Hospital, 1620 Tremont Street, OBC 3 12J, Boston, MA 02120, USA
    Thromb Haemost 106:572-84. 2011
    ....
  35. doi request reprint Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials
    Sripal Bangalore
    New York University School of Medicine, New York, USA
    Arch Neurol 68:172-84. 2011
    ..The role of carotid artery stenting (CAS) when compared with carotid endarterectomy (CEA) is controversial, with recent trials showing an increased risk of harm with CAS...
  36. ncbi request reprint Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry)
    Benjamin A Steinberg
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 99:1212-5. 2007
    ..In conclusion, use of evidence-based, guideline-recommended therapies in outpatients with CAD needs to improve, especially in medically managed patients...
  37. doi request reprint Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack
    Jeremiah P Depta
    VA Boston Healthcare System, 1400 VFW Parkway, Boston, MA 02132, USA
    Stroke 43:2376-81. 2012
    ..We studied the clinical outcomes associated with platelet function-guided modifications in antiplatelet therapy in patients with ischemic stroke or transient ischemic attack...
  38. doi request reprint Role of antiplatelet therapy across the spectrum of patients with coronary artery disease
    Deepak L Bhatt
    Veterans Affairs Boston Healthcare System, and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 103:11A-19A. 2009
    ....
  39. doi request reprint Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 123:1854-63. 2011
    ..The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD...
  40. ncbi request reprint Contemporary management of peripheral arterial disease: III. Endovascular and surgical management
    Amjad Almahameed
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 73:S45-51. 2006
    ....
  41. doi request reprint Antiplatelet therapy in coronary heart disease prevention
    Kumaran Kolandaivelu
    Division of Cardiology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cardiol Clin 29:71-85. 2011
    ..This review provides a current appraisal of antiplatelet drug use in CHD prevention and discusses key barriers to achieving its full potential in real-world practice...
  42. doi request reprint Quality of care and outcomes for in-hospital ischemic stroke: findings from the national get with the guidelines-stroke
    Ethan Cumbler
    From the Department of Medicine, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO E C, H W VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA D L B Duke Clinical Research Institute, Duke University Medical Center, Durham, NC M C, Y X Department of Epidemiology, Michigan State University, East Lansing, MI M R Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada E E S Department of Neurology, Massachusetts General Hospital, Boston, MA L S and Division of Cardiology, Ronald Reagan UCLA Medical Center, Los Angeles, CA G C F
    Stroke 45:231-8. 2014
    ..This study compares patient characteristics, process measures of quality, and outcomes for in-hospital strokes with those for community-onset strokes in a national cohort...
  43. doi request reprint The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 162:818-825.e6. 2011
    ....
  44. doi request reprint Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence
    Kumaran Kolandaivelu
    Veterans Affairs Boston Healthcare System, Brigham and Women s Hospital and Harvard Medical School, 1400 VFW Parkway, Boston, MA 02132, USA
    Nat Rev Cardiol 7:461-7. 2010
    ....
  45. doi request reprint Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort
    Zanfina Ademi
    Melbourne EpiCentre, Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Australia
    Cardiovasc Ther 31:45-52. 2013
    ..To describe aspirin use in primary and secondary prevention and to determine the incremental costs-effectiveness ratio (ICER) per life year gain (LYG) of aspirin use among subjects with, or at high risk of atherothrombotic disease...
  46. doi request reprint Antiplatelet therapy and proton pump inhibition: cause for concern?
    Jeremiah P Depta
    Division of Cardiology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Curr Opin Cardiol 27:642-50. 2012
    ..To review the current evidence on the clinical significance of the drug-drug interactions between the available antiplatelet agents and proton pump inhibitors (PPIs)...
  47. ncbi request reprint Increasing proportion of clinical trials using noninferiority end points
    Venkatesh L Murthy
    Division of Cardiovascular Medicine, Department of Internal Medicine, Cardiovascular Imaging Program, and TIMI Study Group, Brigham and Women s Hospital, and VA Boston Healthcare System, Boston, Massachusetts
    Clin Cardiol 35:522-3. 2012
    ..Drs. Murthy and Desai have received consulting fees from Novo Nordisk. The authors have no other funding, financial relationships, or conflicts of interest to disclose...
  48. doi request reprint Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension
    Bradley A Maron
    Department of Cardiology, Veterans Affairs Boston Healthcare System, West Roxbury, MA, USA
    Crit Pathw Cardiol 11:40-2. 2012
    ..The current work aims to bridge this gap by providing a stepwise procedure for the safe administration of clinically indicated intravenous epoprostenol during pulmonary vasoreactivity testing...
  49. doi request reprint Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator
    Rahul Sakhuja
    Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Am J Cardiol 103:735-41. 2009
    ..7-fold increased mortality risk in patients who receive dialysis compared with those who do not. Beta blockers may be less cardioprotective in patients with ICDs who are on dialysis...
  50. ncbi request reprint Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
    Michael R Tamberella
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA, USA
    Am J Cardiol 89:1429-31. 2002